Radionuclide Tx Wins in Third-Line Metastatic CRPC

(MedPage Today) -- Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy reduced the risk of disease progression or death versus cabazitaxel (Jevtana) in men with previously treated metastatic castration-resistant prostate cancer...